X

Envigo launches PATHWAY, an optimized safety assessment solution to enable first-in-human clinical trials

Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. Read More

Envigo Expands its Bioanalytical Capabilities to Support Increasing Biopharmaceutical Industry Demand

Investments to increase global capacity have been made to support customers’ discovery, preclinical and clinical drug development efforts for small and large molecules. Read More

Envigo to Expand Livermore, California Research Model Surgical Facility to Meet Rising Demand from West Coast Biopharmaceutical Companies

Facility to increase footprint ten-fold and significantly increase surgical technicians, becoming the Envigo West Coast Center of Excellence for surgery. Read More

See All Latest News
Brochure
Envigo oncology brochure (USA | EU)

At Envigo, we understand that our customers conduct research and develop products that have the potential to offer significant improvements to global health and the environment. We also realize achieving that potential has grown more challenging. That is why we remain focused on your goals, needs and expectations, ensuring you have a trusted partner to advance your life-changing research and products.

Article
Developments in LifeSciences Vol. 15, No. 1

In this issue:
• 20 critical questions for ensuring inhaled crop protection and chemical registration
• The CRO landscape — An evolving safety testing market
• Substance identity: The critical component of both lead and co-registrant dossiers
• The extended one-generation reproductive toxicity study (EOGRTS), OECD test guideline 443

Webinar on-demand
Key considerations in the safety evaluation of drugs targeting immune checkpoints

Presented by Lee Coney (Chief Scientific Officer - Biologics) and Mandy Horn (Supervisor - Veterinary Science, Research and Support). You will learn what is cancer immunotherapy; what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?; Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets; and more.

See all scientific insights